1. Home
  2. Vol 51, No 4 (2019)
  3. Subekti

Practical Guidelines Management of Graves Ophthalmopathy

Imam Subekti, Pradana Soewondo, Suharko Soebardi, Budiman Darmowidjojo, Dante Saksono Harbuwono, Dyah Purnamasari, Tri Juli Edi Tarigan, Wismandari Wisnu, Dicky Levenus Tahapary, Farid Kurniawan, M Sidik, Syntia Nusanti, Salmarezka Dewiputri, Hernawita Suharko, Gusti G Suardana, Indrati Suroyo, Vally Wulani, Alvita Dewi Siswoyo, Soehartati Gondhowiardjo, Henry Kodrat

Abstract


Graves’ ophthalmopathy is the most common extra-thyroid manifestation in patients with Graves’ disease, based on inflammatory and autoimmune conditions in orbital tissue. This practical guideline was formed by a multidiciplinary team, and is intended to provide guidance for diagnosis and management of Graves’ ophthalmopathy in daily clinical practice to improve quality of care and treatment outcome.

Keywords


Graves’ ophthalmopathy; diagnosis; management

References


Bartalena L, Baldeschi L, Boboridis K, et al. The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy Guidelines for the Management of Graves’ Orbitopathy. Eur Thyroid J. 2016;5:9–26.

Kartono D. Korelasi antara ketebalan otot ekstraokular pada CT scan orbita dengan derajat oftalmopati graves. FKUI. Jakarta; 2017.

Subekti I. Diagnosis dan pengelolaan oftalmopati Graves. Jakarta Endocrinology Meeting. Jakarta: Divisi Metabolik Endokrinologi, Departemen Ilmu Penyakit Dalam FKUI/RSCM; 2008. p. 30–5.

Subekti I. Hubungan TSH receptor antibody, thyroid stimulating antibody, dan thyroid blocking antibody dengan aktivitas klinis dan derajat keparahan oftalmopati graves. Fakultas Kedokteran Universitas Indonesia. Jakarta.; 2011.

Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016;26(10):1343–421.

Kahaly GJ, Bartalena L, Hegedüs L, Leenhardt L, Poppe K, Pearce SH. 2018 European Thyroid Association Guideline for the Management of Graves’ Hyperthyroidism. Eur Thyroid J. 2018;7:167–86.

Bahn RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: Management Guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr Pr. 2011;21(6):593–646.

Bartalena L, Marcocci C, Pinchera A. Treating severe Graves’ ophthalmopathy. Baillieres Clin Endocrinol Metab. 1997;11(3):521–36.

Tu X, Dong Y, Zhang H, Su Q. Corticosteroids for Graves’ ophthalmopathy: Systematic review and meta-analysis. 2018;2018.

Kahaly GJ, Pitz S, Hommel G, Dittmar M. Randomized, Single blind trial of intravenous versus oral steroid monotherapy in Graves’ orbitopathy. J Clin Endocrinol Metab. 2005;90(9):5234– 40.

Bartalena L, Baldeschi L, Dickinson A, et al. Consensus statement of the European Group on Graves ’ orbitopathy ( EUGOGO ) on management of GO. Eur J Endocrinol. 2008;158:273–85.

Wiersinga WM. Advances in treatment of active, moderate-to-severe Graves’ ophthalmopathy. Lancet Diabetes Endocrinol. 2017;5(2):134–42.

Stan MN, Salvi M. Rituximab therapy for Graves’ orbitopathy – lessons from randomized control trials. Eur J Endocrinol. 2017;176(2):R101-9.

Atienza-Mateo B, V.Calvo-Río, Martín-Varillas JL, Demetrio-Pablo R. Anti-IL6-receptor Tocilizumab in Graves orbitopathy. Multicenter study of 29 patients. Sci Abstr. 2018;SAT0601:1153–4.

Fleming JC, Dailey RA, Tang RA, et al. Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med. 2017;376(18):1748-61.


Full Text: PDF Appendix 1

Refbacks

  • There are currently no refbacks.